{"id":109,"date":"2024-01-30T17:34:18","date_gmt":"2024-01-30T21:34:18","guid":{"rendered":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/?p=109"},"modified":"2024-03-04T17:36:52","modified_gmt":"2024-03-04T21:36:52","slug":"senator-echoes-ftcs-focus-on-improper-listings-and-anticompetition","status":"publish","type":"post","link":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/2024\/01\/30\/senator-echoes-ftcs-focus-on-improper-listings-and-anticompetition\/","title":{"rendered":"Senator Echoes FTC&#8217;s Focus on Improper Listings and Anticompetition"},"content":{"rendered":"<p>In January, Senator Tammy Baldwin (D-WI) <a href=\"https:\/\/www.baldwin.senate.gov\/news\/press-releases\/senator-baldwin-demands-big-pharma-stop-unfair-practices-that-reduce-competition-raise-prices-for-inhalers\">sent letters<\/a> to companies warning of improper Orange Book listings of patents for inhalers, following up on the <a href=\"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2023\/11\/08\/ftc-issues-notice-letters-regarding-orange-book-listings\/\">FTC\u2019s focus<\/a>\u00a0on potential anticompetitive harm of improper listings. According to Senator Baldwin\u2019s letters, the recipients of the letters were warned by the FTC in November regarding the listing of inhaler patents, but have not removed the patents from the Orange Book. The letters follow an\u00a0<a href=\"https:\/\/www.baldwin.senate.gov\/news\/press-releases\/senators-baldwin-colleagues-launch-investigation-into-pharmaceutical-companies-high-price-of-asthma-inhalers\">investigation<\/a>\u00a0launched earlier this month by the Senate Committee on Health, Education, Labor, and Pensions (of which Senator Baldwin is a member) into the prices of inhalers.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In January, Senator Tammy Baldwin (D-WI) sent letters to companies warning of improper Orange Book listings of patents for inhalers, following up on the FTC\u2019s focus\u00a0on potential anticompetitive harm of improper listings. According to Senator Baldwin\u2019s letters, the recipients of the letters were warned by the FTC in November regarding the listing of inhaler patents, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/blogs.duanemorris.com\/antitrustlaw\/2024\/01\/30\/senator-echoes-ftcs-focus-on-improper-listings-and-anticompetition\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Senator Echoes FTC&#8217;s Focus on Improper Listings and Anticompetition&#8221;<\/span><\/a><\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[38,16,34,13,17],"ppma_author":[5],"class_list":["post-109","post","type-post","status-publish","format-standard","hentry","category-general","tag-anticompetition","tag-ftc","tag-orange-book","tag-sarah-olaughlin-kulik","tag-sean-mcconnell"],"authors":[{"term_id":5,"user_id":6,"is_guest":0,"slug":"duanemorris3","display_name":"Duane Morris","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/843ff6e7a8fe5fc92109b47a45f34b6cf0ea499e6e788db23456c838b0ae6747?s=96&d=blank&r=g","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/wp-json\/wp\/v2\/posts\/109","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/wp-json\/wp\/v2\/comments?post=109"}],"version-history":[{"count":0,"href":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/wp-json\/wp\/v2\/posts\/109\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/wp-json\/wp\/v2\/media?parent=109"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/wp-json\/wp\/v2\/categories?post=109"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/wp-json\/wp\/v2\/tags?post=109"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/wp-json\/wp\/v2\/ppma_author?post=109"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}